when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog

← back to Ultragenyx Pharmaceutical Inc.

News mentioning $RARE

828 stories

Aug 27, 26FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adultsfda press

Aug 27, 26Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushfiercebiotech

Aug 27, 26Opinion: I studied Reddit forums on menopause — and found what doctors are missingstat

Aug 27, 26STAT+: The mystery of Moderna’s magic algorithmstat

Aug 27, 26Fragile X at a turning point: Breaking through the clinical bottleneckbiospace

Aug 27, 26CAR Ts will only treat autoimmune diseases if we can scale deliverybiospace

Aug 26, 26Biohaven trades cash for ‘upside’ with $795M epilepsy drug dealbiopharma dive

Aug 26, 26Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialbiopharma dive

Aug 26, 26Biohaven could get up to $795M in epilepsy alliance with SK Biobiospace

Aug 25, 26After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformfiercebiotech

Aug 25, 26J&J’s Imaavy wins label expansion; Two approvals in Japanendpoints

Aug 25, 26STAT+: Turkish antitrust authorities probe Teva for allegedly gaming the patent system, disparaging rival drugsstat

Aug 25, 26STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and morestat

Aug 24, 26Safety concerns spur FDA to again halt testing of Regenxbio gene therapybiopharma dive

Aug 24, 26FDA extends review of Capricor cell therapy; Pain drug startup to go publicbiopharma dive

Aug 24, 26STAT+: Lady Gaga and her fiancé launch a biotech startupstat

Aug 24, 26REGENXBIO’s Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plansbiospace

Aug 24, 26STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and morestat

Aug 24, 26STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concernsstat

Aug 24, 26Option-to-acquire deals remain rare in biotech's buzzy M&A seasonendpoints

Aug 24, 26Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drugfiercebiotech

Aug 24, 26STAT+: Inside Moderna and Merck’s cancer vaccine triumphstat

Aug 24, 26Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findingsfiercebiotech

Aug 24, 26Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alonebiospace

Aug 23, 26Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'fiercebiotech

Aug 22, 26Everything Sprouts, LLC Recalls Alfalfa Sprouts Due to Potential E. Coli and Salmonella Riskfda recalls

Aug 21, 26Lawmakers urge FDA to enact new China policies after 3 gene therapy trial deathsbiospace

Aug 21, 26Werewolf and Ambros to tie the knot in $150M rare disease dealbiospace

Aug 21, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Aug 21, 26STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and morestat

← prevpage 10 of 28next →